{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:46Z","timestamp":1794047446336,"version":"4.8.0"},"reference-count":35,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Osseous involvement by diffuse large B-cell lymphoma (DLBCL-bone) is a heterogeneous disease. There is limited data regarding response assessment by positron emission tomography with fluorodeoxyglucose, which may demonstrate residual avidity despite a complete response. We analyzed clinical data of patients with newly diagnosed DLBCL and identified all cases with DLBCL-bone. End of treatment scans were reviewed by two independent experts classifying osseous lesions into Deauville (DV) \u22643; DV \u22654, or reactive uptake in the bone marrow (M), site of fracture (F) or surgery (S). We compared outcomes of DLBCL-bone to other extranodal sites (EN) matched on International Prognotic Index features and regimen. Of 1,860 patients with DLBCL (bone 16%; EN 45%; nodal 39%), 41% had localized disease and 59% advanced. Only 9% (n=27) of patients with initial bone involvement had residual fluorodeoxyglucose avidity at the osseous site. In half of these cases, the uptake was attributed to F\/S\/M, and of the remaining 13, only two were truly refractory (both with persistent disease at other sites). Overall survival and progression-free survival (PFS) were found to be similar for early- stage nodal DLBCL and DLBCL-bone, but inferior in EN-DLBCL. Advanced-stage disease involving the bone had a similar 5-year PFS to nodal disease and EN-DLBCL. After matching for International Prognotic Index and treatment regiments, PFS between bone and other EN sites was similar. Osseous involvement in DLBCL does not portend a worse prognosis. End of treatment DV \u22654 can be expected in 5-10% of cases, but in the absence of other signs of refractory disease, may be followed expectantly.<\/jats:p>","DOI":"10.3324\/haematol.2022.282643","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:13:34Z","timestamp":1693412014000},"page":"200-208","source":"Crossref","is-referenced-by-count":4,"title":["Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET\/CT and good longterm outcomes"],"prefix":"10.3324","volume":"109","author":[{"given":"Paola","family":"Ghione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Ahsanuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Luttwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela Bobillo","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Navitski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erel","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"56331","doi-asserted-by":"crossref","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66(6):443-459.","DOI":"10.3322\/caac.21357"},{"key":"56332","doi-asserted-by":"crossref","unstructured":"M\u00f8ller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation\u2013a population-based study of 1575 cases. Br J Haematol. 2004; 124(2):151-159.","DOI":"10.1046\/j.1365-2141.2003.04749.x"},{"key":"56333","doi-asserted-by":"crossref","unstructured":"Messina C, Christie D, Zucca E, Gospodarowicz M, Ferreri AJ. Primary and secondary bone lymphomas. Cancer Treat Rev. 2015; 41(3):235-246.","DOI":"10.1016\/j.ctrv.2015.02.001"},{"key":"56334","doi-asserted-by":"crossref","unstructured":"Tao R, Allen PK, Rodriguez A. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015; 92(1):122-129.","DOI":"10.1016\/j.ijrobp.2015.01.014"},{"key":"56335","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) B-Cell Lymphomas Version 3. 2023. Publisher Full Text|"},{"key":"56336","doi-asserted-by":"crossref","unstructured":"Yahalom J, Illidge T, Specht L. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015; 92(1):11-31.","DOI":"10.1016\/j.ijrobp.2015.01.009"},{"key":"56337","doi-asserted-by":"crossref","unstructured":"Vitolo U, Seymour JF, Martelli M. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(Suppl 5):v91-v102.","DOI":"10.1093\/annonc\/mdw175"},{"key":"56338","doi-asserted-by":"crossref","unstructured":"Held G, Zeynalova S, Murawski N. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013; 31(32):4115-4122.","DOI":"10.1200\/JCO.2012.48.0467"},{"key":"56339","doi-asserted-by":"crossref","unstructured":"Lee HY, Kim SJ, Kim K, Ko YH, Kim WS. Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value?. Leuk Lymphoma. 2012; 53(1):173-175.","DOI":"10.3109\/10428194.2011.608452"},{"key":"56340","doi-asserted-by":"crossref","unstructured":"Bhagavathi S, Micale MA, Les K, Wilson JD, Wiggins ML, Fu K. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature. Am J Surg Pathol. 2009; 33(10):1463-1469.","DOI":"10.1097\/PAS.0b013e3181b314ce"},{"key":"56341","doi-asserted-by":"crossref","unstructured":"Messina C, Ferreri AJM, Govi S. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). Br J Haematol. 2014; 164(6):834-840.","DOI":"10.1111\/bjh.12714"},{"key":"56342","doi-asserted-by":"crossref","unstructured":"M\u00fcller A, Dreyling M, Roeder F. Primary bone lymphoma: clinical presentation and therapeutic considerations. J Bone Oncol. 2020; 25:100326.","DOI":"10.1016\/j.jbo.2020.100326"},{"key":"56343","doi-asserted-by":"crossref","unstructured":"Jawad MU, Schneiderbauer MM, Min ES, Cheung MC, Koniaris LG, Scully SP. Primary lymphoma of bone in adult patients. Cancer. 2010; 116(4):871-879.","DOI":"10.1002\/cncr.24828"},{"key":"56344","doi-asserted-by":"crossref","unstructured":"Bobillo S, Joffe E, Lavery JA. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021; 137(1):39-48.","DOI":"10.1182\/blood.2020005112"},{"key":"56345","doi-asserted-by":"crossref","unstructured":"Stephens DM, Li H, Constine LS. Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica. 2022; 107(11):2732-2736.","DOI":"10.3324\/haematol.2022.281004"},{"key":"56346","doi-asserted-by":"crossref","unstructured":"Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005; 23(26):6387-6393.","DOI":"10.1200\/JCO.2005.05.015"},{"key":"56347","doi-asserted-by":"crossref","unstructured":"Juweid ME, Stroobants S, Hoekstra OS. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25(5):571-578.","DOI":"10.1200\/JCO.2006.08.2305"},{"key":"56348","doi-asserted-by":"crossref","unstructured":"Barrington SF, Qian W, Somer EJ. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010; 37(10):1824-1833.","DOI":"10.1007\/s00259-010-1490-5"},{"key":"56349","doi-asserted-by":"crossref","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009; 50(8):1257-1260.","DOI":"10.1080\/10428190903040048"},{"key":"56350","doi-asserted-by":"crossref","unstructured":"Govi S, Christie D, Messina C. The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. Ann Oncol. 2014; 25(1):176-181.","DOI":"10.1093\/annonc\/mdt482"},{"key":"56351","doi-asserted-by":"crossref","unstructured":"Ng AP, Wirth A, Seymour JF. Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma. 2007; 48(3):596-600.","DOI":"10.1080\/10428190601099965"},{"key":"56352","doi-asserted-by":"crossref","unstructured":"Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET\/CT. Eur J Nucl Med Mol Imaging. 2007; 34(1):60-67.","DOI":"10.1007\/s00259-006-0238-8"},{"key":"56353","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"56354","doi-asserted-by":"crossref","unstructured":"Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"56355","doi-asserted-by":"crossref","unstructured":"Moskowitz C, Hamlin PA, Maragulia J, Meikle J, Zelenetz AD. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01\u2013142) without radiotherapy for patients with primary mediastinal large B cell lymphoma. Blood. 2010; 116(21):420.","DOI":"10.1182\/blood.V116.21.420.420"},{"key":"56356","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Sch\u00f6der H, Teruya-Feldstein J. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell Lymphoma. J Clin Oncol. 2010; 28(11):1896-1903.","DOI":"10.1200\/JCO.2009.26.5942"},{"key":"56357","doi-asserted-by":"crossref","unstructured":"Sch\u00f6der H, Polley M-YC, Knopp MV. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020; 135(25):2224-2234.","DOI":"10.1182\/blood.2019003277"},{"key":"56358","doi-asserted-by":"crossref","unstructured":"Poeschel V, Held G, Ziepert M. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019; 394(10216):2271-2281.","DOI":"10.1016\/S0140-6736(19)33008-9"},{"key":"56359","doi-asserted-by":"crossref","unstructured":"Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011; 52(3):386-392.","DOI":"10.2967\/jnumed.110.082586"},{"key":"56360","doi-asserted-by":"crossref","unstructured":"Micallef IN, Maurer MJ, Wiseman GA. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011; 118(15):4053-4061.","DOI":"10.1182\/blood-2011-02-336990"},{"key":"56361","doi-asserted-by":"crossref","unstructured":"Pregno P, Chiappella A, Bell\u00f2 M. Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012; 119(9):2066-2073.","DOI":"10.1182\/blood-2011-06-359943"},{"key":"56362","doi-asserted-by":"crossref","unstructured":"Mikhaeel NG, Hutchings M, Fields PA, O\u2019Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005; 16(9):1514-1523.","DOI":"10.1093\/annonc\/mdi272"},{"key":"56363","doi-asserted-by":"crossref","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, S\u00f6rgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009; 48(2):89-124.","DOI":"10.2165\/00003088-200948020-00002"},{"key":"56364","doi-asserted-by":"crossref","unstructured":"Dubey P, Ha CS, Besa PC. Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys. 1997; 37(5):1087-1093.","DOI":"10.1016\/S0360-3016(97)00106-5"},{"key":"56365","doi-asserted-by":"crossref","unstructured":"Heyning FH, Hogendoorn PC, Kramer MH, Holland CT, Dreef E, Jansen PM. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. J Clin Pathol. 2009; 62(9):820-824.","DOI":"10.1136\/jcp.2008.063156"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282643\/76014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282643\/76441","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11233\/76014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:46Z","timestamp":1794045886000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282643","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}